3 recruiting, 1 active not recruiting, 1 completed. 5 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 5 | Recruiting 3, Active not recruiting 1, Completed 1 |
Follow elacestrant: new trials by email Literature Review of elacestrant trials Research Report on elacestrant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Marker - Adjusted Therapy Comparing Adjuvant Elacestrant With Standard Endocrine Treatment in Genomically and/or Clinically High-risk ER+/HER2- eBC Elacestrant, Standard-of-care endocrine treatment - Breast Cancer, HR+/HER2- Breast Cancer | Phase 3 | Recruiting | Women's Cancer Study Group GmbH | 1520 | 2026-04-29 | 2026-08-07 |
| Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i. Everolimus, Elacestrant, Placebo - Advanced Breast Cancer, ER-positive Breast Cancer | Phase 3 | Recruiting | MedSIR | 300 | 2024-12-05 | 2026-08-24 |
| A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence Elacestrant, Anastrozole, Letrozole - Breast Cancer | Phase 3 | Active not recruiting | Stemline Therapeutics, Inc. | 4556 | 2024-09-27 | 2026-11-04 |
| Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA) Elacestrant, Tamoxifen, Letrozole 2.5mg - ER-positive Breast Cancer, HER2-negative Breast Cancer | Phase 3 | Recruiting | European Organisation for Research and Treatment of Cancer - EORTC | 220 | 2023-12-15 | 2026-10-07 |
| Phase 3 Trial of Elacestrant Versus Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer Elacestrant, Standard of Care - Breast Cancer | Phase 3 | Completed | Stemline Therapeutics, Inc. | 478 | 2019-05-10 | 2025-09-15 |
Breast Neoplasms (4) · Breast Neoplasms, Male (1)
Stemline Therapeutics, Inc. (2) · European Organisation for Research and Treatment of Cancer - EORTC (1) · MedSIR (1) · Women's Cancer Study Group GmbH (1)
France (4) · Germany (4) · Italy (4) · Spain (4) · Austria (3) · Belgium (3) · Greece (3) · Portugal (3) · United Kingdom (3) · Argentina (2) · Australia (2) · Brazil (2) · Canada (2) · Czechia (2) · Denmark (2)
Antonio Llombart-Cussac, M.D., Ph.D. (1) · Emmanouil Saloustros (1) · Michail Ignatiadis (1) · Monika Graeser, PD Dr (1) · NAdia Harbeck, Prof Dr (1) · Oleg Gluz, Prof Dr (1) · Peter Schmid, PHD Dr (1) · Sherko Kuemmel, Prof Dr (1)
PMID 31426673, PMID 35584336, PMID 38381994
2025 (1)